Objectives: A high proportion of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia die within a few days of the onset of infection. However, predictive factors for early mortality (EM) have barely been examined. The aim of this study was to determine the predictive factors for EM in patients with MRSA bacteraemia.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is currently a cause of concern in Spain, where the incidence is 7/100 000 patient days and the percentage of methicillin resistance is 30.
1 Mortality among patients with MRSA bacteraemia is close to 30%. 2 -4 Predictive factors for mortality have been related to host and microorganism characteristics and the interaction between them, and to therapeutic interventions. 5, 6 The impact of host factors on mortality has been extensively analysed; age and comorbidities are the factors identified most frequently. 7 Regarding the interaction between host and MRSA, certain sources of bacteraemia have also been associated with mortality. 8 Some studies have also noted the significance of the setting of acquisition. 9, 10 The influence of high MRSA vancomycin MIC on mortality has been widely debated in recent years.
While some studies report worse outcomes in episodes caused by strains with higher vancomycin MICs, even in the susceptible range, 8, 11 others do not. 12 -16 The impact of distinct MRSA clones on mortality has received little attention. 17, 18 Lastly, inappropriate empirical therapy has been described as a predictor of mortality, 19, 20 but some studies did not find a significant relationship with poor outcome. 21 Although a large proportion of deaths occur within the first few days after the onset of S. aureus bacteraemia, 2,22 predictors of early mortality (EM) have barely been examined. 23 The objective of this study was to determine distinctive predictors of EM in a large cohort of patients with MRSA bacteraemia.
Patients and methods

Study period and patients
The study was conducted from June 2008 to December 2009 in 21 Spanish hospitals. Four centres had ,500 beds, nine had 500-1000 beds and eight had .1000 beds. All consecutive episodes of MRSA bacteraemia observed in adult patients in participating centres were prospectively followed using a standardized protocol. Cases that did not meet the inclusion criteria because of a lack of signs and symptoms consistent with sepsis were excluded. Strains were sent to a central laboratory for further studies.
Study design
Patients with MRSA bacteraemia were classified into three groups according to outcome: (i) patients with EM; (ii) patients with late mortality (LM); and (iii) survivors. With the data, we carried out univariate and multivariate analyses to assess the predictive factors for EM. Then, following the methodology described by Harris et al., 24 two separate analyses were performed: the first compared patients with EM and survivors and the second compared patients with LM and survivors. Variables with statistical significance in the first analysis but not in the second were considered distinctive factors for EM; those that were significant only in the second analysis were considered distinctive predictors of LM.
Definitions
MRSA bacteraemia was defined as the presence of at least one positive blood culture for MRSA in a blood sample from a patient with clinical findings consistent with infection. 25 Comorbidity was measured by the Charlson score, 26 which stratifies the associated diseases on an ordinal scale. Patients were classified into three categories on the McCabe scale, 27 according to their vital prognosis before the MRSA bacteraemia: non-fatal if death was expected within a period of .5 years; ultimately fatal if death was expected between 1 and 5 years; and rapidly fatal if it was expected within the following year. Severity of sepsis in the acute condition was assessed by the Pitt score. 28 According to the Friedman criteria, 29 three acquisition categories were considered: (i) nosocomial bacteraemia if the episode was diagnosed at least 48 h after admission to an ICU or a conventional (non-ICU) hospital ward and if there were no signs or symptoms of infection at admission; (ii) healthcare-related bacteraemia if previous contact with the healthcare system was recorded within the previous 3 months; and (iii) community acquisition if the episode did not fit the previous conditions. The source of the bacteraemia was defined according to the CDC criteria. 30 Bacteraemia from an unknown source (primary) was defined when the origin was uncertain after careful examination of the clinical and microbiological data. Distant extension was diagnosed with the presence of at least one distant infection secondary to blood spread seeding. The initial antibiotic was defined as the antibiotic administered in the first 48 h after the onset of bacteraemia, independently of the microbiological information. Initial antibiotic treatment was considered appropriate if the strain was susceptible to at least one of the antibiotics administered according to the current CLSI breakpoints, 31 with the exception of aminoglycosides, which were considered inappropriate regardless of the susceptibility test results. Source was considered eradicated if the catheter or foreign body was removed, if surgery on the source was carried out or if the bacteraemia source was drained. For outcomes, mortality was defined as in-hospital death from any cause occurring in the 30 days after the onset of MRSA bacteraemia. Mortality was defined as EM for patients who died within the first 2 days and LM for patients who died later.
Susceptibility testing and molecular epidemiology of MRSA isolates
Each hospital identified the strain and performed preliminary susceptibility tests. Isolates were sent to a central reference laboratory. All S. aureus were identified by latex agglutination (Pastorex Staph-plus, Bio-Rad Laboratories, Madrid, Spain) and DNase production (DNasE-test Agar, bioMérieux, Marcy l'Étoile, France). Antimicrobial susceptibility of all MRSA isolates was tested by the disc diffusion method according to the CLSI guidelines. 31 The antimicrobial agents tested were penicillin, oxacillin, cefoxitin, erythromycin, clindamycin, gentamicin, tobramycin, ciprofloxacin, rifampicin, trimethoprim/sulfamethoxazole, tetracycline, fosfomycin, vancomycin, teicoplanin, chloramphenicol, daptomycin and linezolid. MICs were determined by the microdilution method in accordance with CLSI criteria by using commercial panels (ESTEN 2009, Sensititre TM , Izasa, Barcelona, Spain) read visually. Vancomycin MICs were also determined by Etest (bioMérieux) on Mueller-Hinton agar, using a turbidity equivalent to that of a 0.5 McFarland standard.
PFGE was performed after SmaI restriction of chromosomal DNA. 32 Restriction patterns were interpreted in accordance with criteria published elsewhere. 33 Representative isolates of each PFGE type and subtype were studied to determine the multilocus sequence type (MLST) 34 and the staphylococcal chromosome cassette mec (SCCmec) type. 35 MLSTs and SCCmec types were further inferred for all the strains. The agr polymorphism and the presence of genes encoding class S (lukS-PV) and class F (lukF-PV) proteins for Panton-Valentine leucocidin (PVL) were studied by PCR in all the isolates, following the methodology described elsewhere. 36, 37 Statistical analysis Continuous variables were compared using Student's t-test or the MannWhitney U-test as appropriate. Qualitative and stratified continuous variables were compared using Fisher's exact test or Pearson's x 2 test. Relative risks were calculated with 95% CIs in a univariate analysis. The multivariate analyses were performed by using logistic regression models. All the variables with theoretical clinical significance and those that achieved a P value ,0.10 in the univariate analysis were included in the multivariate analysis and adjusted ORs were calculated with 95% CIs. Analyses were performed using SPSS v15 (Microsoft, USA).
Ethics considerations
The study was approved by the Spanish Network for Research in Infectious Diseases (REIPI) and by the Institutional Review Board at each participating centre. Because no direct patient contact was planned, the requirement for informed consent was waived. The data were de-identified in each centre and only then transferred for analysis.
Results
Overall, 590 episodes of MRSA bacteraemia were recorded. Eleven of them were excluded due to the lack of complete information. Therefore, 579 episodes were finally included in the analysis. One hundred and seventy-nine patients (31%) died: 49 (8.5%) were defined as EM and 130 (22.5%) as LM. There were 400 (69%) survivors.
Risk factors for EM
The cohort of patients with EM (n¼49) was compared with the rest (n¼ 530). Clinical and microbiological characteristics and therapeutic interventions were included in the univariate and multivariate analyses. Independent risk factors for EM according to logistic regression analysis were rapidly fatal disease (OR 3.67; P ¼ 0.012), respiratory and unknown sources (OR 3.76; P ¼0.014 and 2.83; P¼ 0.029 respectively), non-nosocomial acquisition (OR 2.59; P ¼0.021), Pitt score of ≥3 (OR 3.99; P ¼ 0.001) and inappropriate initial antibiotic therapy within the first 2 days (OR 3.59; P ¼ 0.001). No microbiological characteristics, such as agr type, clonal complex characterization, PVL or vancomycin MIC, were significantly related to EM (Table 1) . A comparison of the two models showed that for patients with EM inappropriate initial antibiotic therapy within the first 2 days was an independent distinctive factor (Figure 1) , while endocarditis and lower respiratory tract sources were distinctive factors for LM. Old age, rapidly fatal disease, unknown source and Pitt score were associated with mortality in both groups.
Distinctive predictive factors for EM and LM
Multivariate analysis to identify distinctive predictors for EM and LM are shown in Tables 2 and 3. Survivors and non-survivors were compared. Patients with EM (n¼ 49) were more likely to be aged .70 years than survivors (OR 2.77; P ¼ 0.026), more likely to have
Discussion
More than 20 years since the dissemination of MRSA strains in Spanish hospitals, our knowledge of this microorganism has significantly improved. However, mortality of patients with MRSA bacteraemia remains high, close to 30%. 38 In this large multicentre, prospective study we found that a considerable proportion of allcause deaths among patients with MRSA bacteraemia occurred in the first 2 days after onset. Inappropriate antibiotic therapy was identified as a distinctive predictor of EM, and endocarditis and lower respiratory tract sources were identified as predictors of LM.
Although this issue has not been specifically studied to date, we infer that about 50% of non-survivors may die within the first 4 -9 days after the onset of staphylococcal bacteraemia.
3,39,40 To our knowledge, there are no studies that analyse in detail the factors associated with EM. However, a recent population study from the UK found a rate of EM of 11% and reported that the highest risk of death (4.5%) was during the first day of bacteraemia. 23 The absence of clinical, microbiological and treatment data in that study limits the possibility of further analysis regarding the risk factors for EM.
Studies that have examined the relationship between inappropriate empirical therapy and mortality in S. aureus and MRSA bacteraemia have yielded conflicting results. Although some studies did not find a significant association, 21 ,41,42 many others did: Soriano et al. 10 identified inappropriate therapy as a predictor of related mortality, with an OR of 2.13, as did Rodríguez-Bañ o et al. 20 in a cohort of healthcare-acquired sepsis due to MRSA (OR 3.0). Marchaim et al. 43 identified a delay of 2 days in receiving appropriate antibiotic therapy as a predictor of in-hospital mortality (OR 2.35) and Paul et al. 19 reported a significant association with 30 day mortality. Lodise and McKinnon 4 also found an association with 30 day mortality (OR 2.1) and infection-related death (OR 2.2). Lastly, a delay in adequate antibiotic therapy of .44.76 h was identified as an independent predictor of related mortality (OR 3.8) in patients with S. aureus bacteraemia. 22 In the study by Lodise and McKinnon, 4 MRSA was an independent predictor of delayed therapy. In our opinion, the identification of inappropriate initial antibiotic therapy as the distinctive predictor of EM supports the hypothesis that the use of 30 day mortality rate may be an excessively crude way of assessing the impact of initial antibiotic therapy. Our results reinforce the importance of ensuring early administration of adequate antibiotic treatment when MRSA bacteraemia is a diagnostic possibility. As in other studies, 19 a great Early mortality in MRSA bacteraemia proportion of patients in our series received inappropriate coverage, especially when acquisition was non-nosocomial (data not shown). This is a striking observation since risk factors for MRSA bacteraemia at hospital admission are well established, 44 ,45 the most significant one being referral from a long-term care facility and prior MRSA colonization. This information should be taken into account to avoid unnecessary delays in the administration of appropriate antibiotic therapy.
Our study has some limitations. First, our definition of appropriate antibiotic therapy is controversial: antibiotics classified as inadequate, such as aminoglycosides, may have some effect on MRSA. Also, glycopeptides were classified as appropriate regardless of serum levels, which were not always assessed in the first 48 h. In contrast, some bacteriostatic antibiotics classified as appropriate would not usually be used as first choice against MRSA bacteraemia, as other authors have previously pointed out. 46, 47 Second, differences between centres regarding the clinical management and early suspicion of the infection as well as time until the microbiological identification of susceptibility patterns and the presence of the gene mecA may confound the evaluation of antibiotic therapy during the first 2 days.
In summary, our experience suggests that inappropriate antibiotic treatment plays a crucial role in EM among patients with MRSA bacteraemia. Strategies to ensure the adequacy of empirical antibiotic therapy are needed. 
